IL259055B - Cancer treatment methods using b-raf inhibitors and immune checkpoint inhibitors - Google Patents

Cancer treatment methods using b-raf inhibitors and immune checkpoint inhibitors

Info

Publication number
IL259055B
IL259055B IL259055A IL25905518A IL259055B IL 259055 B IL259055 B IL 259055B IL 259055 A IL259055 A IL 259055A IL 25905518 A IL25905518 A IL 25905518A IL 259055 B IL259055 B IL 259055B
Authority
IL
Israel
Prior art keywords
inhibitors
methods
treating cancer
immune checkpoint
raf
Prior art date
Application number
IL259055A
Other languages
English (en)
Hebrew (he)
Other versions
IL259055A (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL259055A publication Critical patent/IL259055A/en
Publication of IL259055B publication Critical patent/IL259055B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL259055A 2015-11-19 2018-04-30 Cancer treatment methods using b-raf inhibitors and immune checkpoint inhibitors IL259055B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257645P 2015-11-19 2015-11-19
PCT/US2016/062859 WO2017087851A1 (en) 2015-11-19 2016-11-18 Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
IL259055A IL259055A (en) 2018-06-28
IL259055B true IL259055B (en) 2022-05-01

Family

ID=57485956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259055A IL259055B (en) 2015-11-19 2018-04-30 Cancer treatment methods using b-raf inhibitors and immune checkpoint inhibitors

Country Status (12)

Country Link
US (3) US20180256552A1 (ja)
EP (1) EP3377107B1 (ja)
JP (1) JP6952691B2 (ja)
CN (1) CN108136022A (ja)
AU (1) AU2016355320B2 (ja)
CA (1) CA3004348A1 (ja)
ES (1) ES2824120T3 (ja)
HK (1) HK1256367A1 (ja)
IL (1) IL259055B (ja)
MX (1) MX2018006152A (ja)
PL (1) PL3377107T3 (ja)
WO (1) WO2017087851A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268392A2 (en) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PL3400246T3 (pl) 2016-01-08 2021-03-08 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018278327B2 (en) * 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
EA202090739A1 (ru) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. Белки, связывающие антиген созревания в-клеток
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3867409A1 (en) * 2018-10-16 2021-08-25 Novartis AG Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2021016228A1 (en) * 2019-07-22 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute Inc. Combination therapy for treating ras-mutant cancers
US20240239895A1 (en) * 2021-04-09 2024-07-18 Genentech, Inc. Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
BRPI0908268A2 (pt) 2008-02-29 2018-10-30 Array Biopharma Inc compostos do inibidor de raf e seus métodos de uso
JP2011513330A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
JP2011513329A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
EP2265574A1 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
PT2884979T (pt) * 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
EP3003316B1 (en) * 2013-05-31 2020-07-22 Merck Sharp & Dohme Corp. Combination therapies for cancer
AU2014276440A1 (en) * 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor

Also Published As

Publication number Publication date
PL3377107T3 (pl) 2020-12-14
MX2018006152A (es) 2018-09-17
HK1256367A1 (zh) 2019-09-20
ES2824120T3 (es) 2021-05-11
AU2016355320A1 (en) 2018-05-17
CA3004348A1 (en) 2017-05-26
IL259055A (en) 2018-06-28
JP6952691B2 (ja) 2021-10-20
US20200155520A1 (en) 2020-05-21
US20180256552A1 (en) 2018-09-13
EP3377107A1 (en) 2018-09-26
AU2016355320B2 (en) 2023-12-07
EP3377107B1 (en) 2020-08-12
KR20180081591A (ko) 2018-07-16
JP2018534311A (ja) 2018-11-22
US20240115555A1 (en) 2024-04-11
WO2017087851A1 (en) 2017-05-26
CN108136022A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
HK1256367A1 (zh) 使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
IL283908A (en) A method of treating cancer by inhibiting an immune checkpoint in combination with an additional therapeutic agent
PT3322731T (pt) Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
HK1253093A1 (zh) 診斷和治療癌症的方法
HK1256380A1 (zh) 修飾的細胞和治療方法
HK1251408A1 (zh) 治療癌症的方法
IL251669A0 (en) Cancer treatment using a tlr9 agonist with checkpoint inhibitors
IL260199B (en) Cancer treatment methods
HK1251862A1 (zh) 治療癌症的方法和組合物
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
RS62007B1 (sr) Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
IL259801A (en) ezh2 inhibitors and methods of using them
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
HK1243407A1 (zh) Ripk2抑制劑及用其治療癌症的方法
HK1251927A1 (zh) 用於治療癌症的新穎生物標記和方法
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
HUE058190T2 (hu) Enoláz inhibitorok és ezekkel történõ kezelési eljárások
GB201418640D0 (en) Agents and methods for treatment of cancer